In this newly created role, Florence Vicaire will be responsible for the continued expansion of the company’s enabling portfolio of biomanufacturing technologies
Univercells Technologies, a provider of biomanufacturing technologies for the production of advanced therapies, has announced the appointment of Florence Vicaire as Chief Commercial Officer (CCO).
Vicaire will be responsible for the commercialisation and continued expansion of the company's enabling portfolio of biomanufacturing technologies and services, which include the scale-X and NevoLine platforms.
"This appointment reflects our commitment to strategic development and expansion within the gene therapy market. We are investing in a sustainable and scalable infrastructure driven by leaders that we are confident in," said Univercells Technologies' CEO Mathias Garny.
I plan to build a deeper commercial foundation for the company, bringing the concepts of integration and intensification
Florence joins this team with many years of global experience in sales and leadership in Life Sciences that will benefit our employees and customers, as Univercells Technologies enters the next stage of growth. Her track record of strong commercial leadership will be crucial as we step forward and expand the existing product line, while investigating new markets and modalities to develop and launch innovative products and services.
Speaking about her new role, Vicaire said: "When I connected with the talented and motivated Univercells Technologies team, I was impressed by their high level of standards. The team is passionate about finding meaningful game changing solutions to critical biomanufacturing challenges in the rapidly growing market for next generation therapies."
Vicaire continued: "As I begin this appointment, I plan to build a deeper commercial foundation for the company. Bringing the concepts of integration and intensification to bioprocessing will offer solutions that contribute to the development of life-saving therapies."
Vicaire brings extensive experience in developing and structuring businesses in life sciences and bioprocess sectors across Europe, Asia, and the US, most recently as Gene Therapy Global Business Leader at Cytiva. Previously, she played a key role in successfully commercialising the iCELLis bioreactor portfolio at ATMI Life Sciences, as well as founding and serving as CEO for a point of care diagnostic biotech start-up.
Vicaire holds an engineering degree in Biotechnology from the UTC Compiègne and an MBA in Marketing and Business Management from the ESSEC business school.